To date, therapeutic strategies to target C9 ALS/FTD repeat RNAs have focused on targeting the sense G4C2 repeat transcripts12–16, however, there is a considerable and growing body of evidence that supports the contribution of the antisense strand to C9 ALS/FTD disease pathogenesis17–21. This evidence concerns the gene C9 and frontotemporal dementia.